Short-term teriparatide delivery and osseointegration: a clinical feasibility study.

Kuchler U, Luvizuto ER, Tangl S, Watzek G, Gruber R

Journal of dental research9 May 2011Cited by 33 (Europe PMC)

PMID21555773DOI10.1177/0022034511407920PepBankPUB-21555773

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In participants with edentulous lower jaws, median periosteal NBV/TV was 17.6% with teriparatide versus 15.4% without treatment.
In plain wordsIn people with toothless lower jaws, periosteal new bone volume was higher with teriparatide than without treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePeriosteal NBV/TV
Study
n = 23
Comparator
No treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg once daily · 28 daysAs given in this study (human).
Measurements
NBV/TV median (periosteal)
17.6%
teriparatide
NBV/TV median (periosteal)
15.4%
control (no treatment)
Source sentences
Summary
We report here that median values of NBV/TV in the control and the teriparatide groups were 15.4% vs. 17.6% in the periosteal compartment, 11.3% vs. 16.5% in the cortical compartment, and 7.3% vs. 12.0% in the medullary compartment, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted an open-label randomized controlled feasibility study and included 24 individuals with edentulous lower jaws.
Summary · context
They were randomly assigned to receive either 20 µg of teriparatide once daily for 28 days or no treatment.
Summary · context
Study implants were retrieved from 23 participants after 9 weeks and were subjected to histomorphometric analyses.
Report a problemFND-2155577301
02HumanRandomized controlled trialEfficacy outcome
In participants with edentulous lower jaws, median cortical NBV/TV was 16.5% with teriparatide versus 11.3% without treatment.
In plain wordsIn people with toothless lower jaws, cortical new bone volume was higher with teriparatide than without treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical NBV/TV
Study
n = 23
Comparator
No treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg once daily · 28 daysAs given in this study (human).
Measurements
NBV/TV median (cortical)
16.5%
teriparatide
NBV/TV median (cortical)
11.3%
control (no treatment)
Source sentences
Summary
We report here that median values of NBV/TV in the control and the teriparatide groups were 15.4% vs. 17.6% in the periosteal compartment, 11.3% vs. 16.5% in the cortical compartment, and 7.3% vs. 12.0% in the medullary compartment, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted an open-label randomized controlled feasibility study and included 24 individuals with edentulous lower jaws.
Summary · context
They were randomly assigned to receive either 20 µg of teriparatide once daily for 28 days or no treatment.
Summary · context
Study implants were retrieved from 23 participants after 9 weeks and were subjected to histomorphometric analyses.
Report a problemFND-2155577302
03HumanRandomized controlled trialEfficacy outcome
In participants with edentulous lower jaws, median medullary NBV/TV was 12.0% with teriparatide versus 7.3% without treatment.
In plain wordsIn people with toothless lower jaws, medullary new bone volume was higher with teriparatide than without treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMedullary NBV/TV
Study
n = 23
Comparator
No treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg once daily · 28 daysAs given in this study (human).
Measurements
NBV/TV median (medullary)
12%
teriparatide
NBV/TV median (medullary)
7.3%
control (no treatment)
Source sentences
Summary
We report here that median values of NBV/TV in the control and the teriparatide groups were 15.4% vs. 17.6% in the periosteal compartment, 11.3% vs. 16.5% in the cortical compartment, and 7.3% vs. 12.0% in the medullary compartment, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted an open-label randomized controlled feasibility study and included 24 individuals with edentulous lower jaws.
Summary · context
They were randomly assigned to receive either 20 µg of teriparatide once daily for 28 days or no treatment.
Summary · context
Study implants were retrieved from 23 participants after 9 weeks and were subjected to histomorphometric analyses.
Report a problemFND-2155577303
04HumanRandomized controlled trialEfficacy outcome
In participants with edentulous lower jaws, median periosteal NBIC was 4.1% with teriparatide versus 3.3% without treatment.
In plain wordsIn people with toothless lower jaws, periosteal new bone contact was higher with teriparatide than without treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePeriosteal NBIC
Study
n = 23
Comparator
No treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg once daily · 28 daysAs given in this study (human).
Measurements
NBIC median (periosteal)
4.1%
teriparatide
NBIC median (periosteal)
3.3%
control (no treatment)
Source sentences
Summary
NBIC median values in the control and the teriparatide groups were 3.3% vs. 4.1% in the periosteal compartment, 5.0% vs. 4.4% in the cortical compartment, and 0.3% vs. 1.4% in the medullary compartment, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted an open-label randomized controlled feasibility study and included 24 individuals with edentulous lower jaws.
Summary · context
They were randomly assigned to receive either 20 µg of teriparatide once daily for 28 days or no treatment.
Summary · context
Study implants were retrieved from 23 participants after 9 weeks and were subjected to histomorphometric analyses.
Report a problemFND-2155577304
05HumanRandomized controlled trialEfficacy outcome
In participants with edentulous lower jaws, median cortical NBIC was 4.4% with teriparatide versus 5.0% without treatment.
In plain wordsIn people with toothless lower jaws, cortical new bone contact was lower with teriparatide than without treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseCortical NBIC
Study
n = 23
Comparator
No treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg once daily · 28 daysAs given in this study (human).
Measurements
NBIC median (cortical)
4.4%
teriparatide
NBIC median (cortical)
5%
control (no treatment)
Source sentences
Summary
NBIC median values in the control and the teriparatide groups were 3.3% vs. 4.1% in the periosteal compartment, 5.0% vs. 4.4% in the cortical compartment, and 0.3% vs. 1.4% in the medullary compartment, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted an open-label randomized controlled feasibility study and included 24 individuals with edentulous lower jaws.
Summary · context
They were randomly assigned to receive either 20 µg of teriparatide once daily for 28 days or no treatment.
Summary · context
Study implants were retrieved from 23 participants after 9 weeks and were subjected to histomorphometric analyses.
Report a problemFND-2155577305
06HumanRandomized controlled trialEfficacy outcome
In participants with edentulous lower jaws, median medullary NBIC was 1.4% with teriparatide versus 0.3% without treatment.
In plain wordsIn people with toothless lower jaws, medullary new bone contact was higher with teriparatide than without treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMedullary NBIC
Study
n = 23
Comparator
No treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg once daily · 28 daysAs given in this study (human).
Measurements
NBIC median (medullary)
1.4%
teriparatide
NBIC median (medullary)
0.3%
control (no treatment)
Source sentences
Summary
NBIC median values in the control and the teriparatide groups were 3.3% vs. 4.1% in the periosteal compartment, 5.0% vs. 4.4% in the cortical compartment, and 0.3% vs. 1.4% in the medullary compartment, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted an open-label randomized controlled feasibility study and included 24 individuals with edentulous lower jaws.
Summary · context
They were randomly assigned to receive either 20 µg of teriparatide once daily for 28 days or no treatment.
Summary · context
Study implants were retrieved from 23 participants after 9 weeks and were subjected to histomorphometric analyses.
Report a problemFND-2155577306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT06061354

Teriparatide on Maxillary Sinus Floor Osseointegration

Universidad de Valparaison = 4223 Aug 2023 to est. Dec 2024

Bone Regeneration

Trial page ClinicalTrials.govUpdated 30 Nov 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.